We are live on
!
Find out more
CA
CHI Advisors Portfolio holdings
AUM
$252M
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter
Est. Return
+63.01%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$372M
AUM Growth
+$110M
(+42%)
Cap. Flow
+$14.9M
Cap. Flow
% of AUM
4.02%
Top 10 Holdings %
Top 10 Hldgs %
85.87%
Holding
30
New
2
Increased
12
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pliant Therapeutics
PLRX
|
+$5.8M |
| 2 |
RPTX
Repare Therapeutics
RPTX
|
+$5.45M |
| 3 |
Larimar Therapeutics
LRMR
|
+$4.76M |
| 4 |
Keros Therapeutics
KROS
|
+$3.36M |
| 5 |
Cullinan Oncology
CGEM
|
+$2.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
+$5.06M |
| 2 |
TSVT
2seventy bio
TSVT
|
+$4.3M |
| 3 |
Nkarta
NKTX
|
+$3.44M |
| 4 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$3.21M |
| 5 |
Entrada Therapeutics
TRDA
|
+$1.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.68% |
| 2 | Miscellaneous | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KZR
26
CALL
DELISTED
Kezar Life Sciences
KZR
| – | – |
-10,000
| Closed | -$5K |
|
|
27
Entrada Therapeutics
TRDA
$283M
| – | – |
-163,496
| Closed | -$1.99M |
|
28
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
| – | – |
-157,000
| Closed | -$372K |
|
|
EIGR
29
CALL
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – |
-837
| Closed | -$4K |
|
|
PHAS
30
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| – | – |
-750,000
| Closed | -$450K |
|
Similar funds
SC
T
W
RBGI
TOGEPT
IAM
RCGI
AEPLI
CHI Advisors's Q3 2022 Portfolio in Review
As of Q3 2022, CHI Advisors held 30 positions worth $372M, up 42% from $262M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
CHI Advisors deployed $14.9M of net new capital in Q3 2022, opening 2 new positions and adding to 12 existing holdings. Its largest new stake was Rallybio: 24,287 shares worth $2.81M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was G1 Therapeutics, Inc. Common Stock, an estimated $5.06M trimmed.
- CHI Advisors's largest Q3 2022 buy was Rallybio: 24,287 shares worth $2.81M.
- CHI Advisors added most to Pliant Therapeutics in Q3 2022, an estimated $5.8M increase.
- CHI Advisors's biggest Q3 2022 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $5.06M.
- CHI Advisors fully exited Entrada Therapeutics in Q3 2022, selling an estimated $1.99M.
- CHI Advisors's ten largest holdings make up 86% of its $372M portfolio in Q3 2022.
- CHI Advisors opened 2 new positions and closed 5 in Q3 2022.
- CHI Advisors's portfolio value rose 42% quarter-over-quarter to $372M.
Based on CHI Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.